Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.</li><li> The company released its full-year 2024 results and updated investors on the tremendous progress made.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company released its full-year 2024 results and updated investors on the tremendous progress made.

EVAX:  Company Lays Out Ambitious 2025 Plan

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.</li><li> The company announced that a key Phase 2 trial was being extended due to the positive results seen to this point, which is a very positive sign for the treatment potential of EVX-01.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company announced that a key Phase 2 trial was being extended due to the positive results seen to this point, which is a very positive sign for the treatment potential of EVX-01.

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of the AI technology.</li><li> The company announced that it has close a public offering of almost four million American Depository Shares, resulting in an additional of over $10 million in cash to its balance sheet.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of the AI technology. The company announced that it has close a public offering of almost four million American Depository Shares, resulting in an additional of over $10 million in cash to its balance sheet.

Denmark

Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Evaxion Biotech A/S (EVAX US)

EVAX: Company Lays Out Ambitious 2025 Plan

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Company Lays Out Ambitious 2025 Plan

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Extended Trial is Excellent News

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Bolsters Balance Sheet

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Bolsters Balance Sheet

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)